In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wk. Nachman A, Chagla Z. Ann Intern Med 2025;178:JC19.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nachman A, Chagla Z. In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wk. Ann Intern Med 2025;178:JC19.
PMID: 39899859